Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus MYCITRACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus MYCITRACIN.
DEXASPORIN vs MYCITRACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
MYCITRACIN is a combination of bacitracin and neomycin, which are aminoglycoside antibiotics. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits. Neomycin binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
500 mg orally every 6 hours
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Terminal elimination half-life is 2–3 hours in adults with normal renal function. Prolonged significantly in renal impairment (up to 24–48 hours in anuria).
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Primarily renal (glomerular filtration and tubular secretion); >90% of dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Corticosteroid/Antibiotic Combination
Antibiotic Combination